Ontology highlight
ABSTRACT:
SUBMITTER: Samra B
PROVIDER: S-EPMC7275444 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Samra Bachar B Jabbour Elias E Ravandi Farhad F Kantarjian Hagop H Short Nicholas J NJ
Journal of hematology & oncology 20200605 1
Recent years have witnessed major advances that have improved outcome of adults with acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual disease has fine-tuned our prognostic models and guided our treatment decisions. The treatment paradigms of ALL have been revolutionized with the advent of tyrosine kinase inhibitors targeting BCR-ABL1, monoclonal antibodies targeting CD20 (rituximab), antibody-drug conjugates targeting CD22 (inotuzumab ozogamicin), bispecifi ...[more]